Bristol-Myers Squibb Company
NYSE: BMY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Updated 2026-06-05
Bristol-Myers Squibb Company (BMY) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.57B | $26.17B | $29.49B | $31.01B | $31.08B | $32.97B | $35.90B | $38.59B | $33.75B | $31.75B | $33.71B | $33.55B | $34.99B | $129.94B | $118.48B | $109.31B | $96.82B | $95.16B | $92.60B | $90.04B |
| Cash & equivalents | $2.02B | $1.80B | $7.98B | $7.68B | $5.03B | $5.78B | $1.66B | $3.59B | $5.57B | $2.38B | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Current assets | $10.30B | $10.35B | $14.70B | $13.96B | $13.27B | $15.32B | $9.52B | $18.92B | $14.61B | $10.41B | $13.70B | $14.85B | $17.72B | $29.35B | $30.19B | $33.26B | $27.27B | $31.77B | $29.78B | $29.39B |
| Total liabilities | $15.58B | $15.61B | $17.28B | $16.22B | $15.44B | $17.10B | $22.26B | $23.36B | $18.77B | $17.32B | $17.36B | $21.70B | $20.86B | $78.25B | $80.60B | $73.31B | $65.70B | $65.67B | $76.22B | $71.53B |
| Current liabilities | $6.50B | $8.64B | $6.71B | $6.31B | $6.74B | $7.78B | $8.28B | $12.44B | $8.46B | $8.02B | $8.84B | $9.56B | $10.65B | $18.30B | $19.08B | $21.87B | $21.89B | $22.26B | $23.77B | $23.42B |
| Long-term debt | $7.25B | $4.38B | $6.58B | $6.13B | $5.33B | $5.38B | $6.57B | $7.98B | $7.24B | $6.55B | $5.72B | $6.97B | $5.65B | $43.39B | $48.34B | $39.60B | $35.06B | $36.65B | $47.60B | $42.85B |
| Shareholder equity | $9.99B | $10.56B | $12.24B | $14.84B | $15.71B | $15.96B | $13.62B | $15.15B | $14.85B | $14.27B | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
| Retained earnings | $19.84B | $19.76B | $22.55B | $30.76B | $31.64B | $33.07B | $32.73B | $32.95B | $32.54B | $31.61B | $33.51B | $31.16B | $34.06B | $34.47B | $21.28B | $23.82B | $25.50B | $28.77B | $14.91B | $16.90B |
| Accounts receivable | $3.25B | $4.24B | $3.64B | $3.16B | $3.48B | $3.74B | $3.08B | $3.36B | $3.39B | $4.30B | $5.54B | $6.30B | $5.75B | $7.68B | $10.55B | $12.52B | $13.94B | $15.26B | $14.42B | $14.53B |
| Inventory | $2.08B | $2.16B | $1.76B | $1.41B | $1.20B | $1.38B | $1.66B | $1.50B | $1.56B | $1.22B | $1.24B | $1.17B | $1.20B | $4.29B | $2.07B | $2.10B | $2.34B | $2.66B | $2.56B | $2.69B |
| Goodwill | $4.83B | $5.00B | $4.83B | $5.22B | $5.23B | $5.59B | $7.63B | $7.10B | $7.03B | $6.88B | $6.88B | $6.86B | $6.54B | $22.49B | $20.55B | $20.50B | $21.15B | $21.17B | $21.72B | $21.75B |
Frequently asked questions
What is Bristol-Myers Squibb Company's revenue?
Bristol-Myers Squibb Company's trailing twelve-month revenue is $48.48B, and consensus projects about $50.50B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is BMY?
In its most recent fiscal year, BMY ran a gross margin of 67.65%, an operating margin of 26.34%, and a net margin of 14.63%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BMY generate?
BMY produced $12.85B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BMY's balance sheet healthy?
BMY holds $10.21B in cash and equivalents against $42.85B in long-term debt, on $18.47B of shareholder equity. That debt is best read against the cash flow the business throws off each year.